Surgical Management of Pancreaticoduodenectomy

Preoperative Considerations

The American Gastroenterological Association recommends that Whipple's pancreaticoduodenectomy should be performed in specialized centers by experienced surgeons to ensure optimal outcomes, with pylorus preservation being the preferred approach for appropriate candidates due to improved nutritional outcomes and quality of life 1, 2, 3
Resectability rates are higher (approximately 20%) in specialized centers due to better patient selection 1, 2
Surgical volume correlates with outcomes - centers and surgeons performing more procedures have significantly lower mortality rates 1, 2

Pylorus-preserving pancreaticoduodenectomy is currently the procedure of choice for tumors of the pancreatic head, offering comparable survival to standard Whipple with potential advantages in nutritional status and reduced post-gastrectomy complications 1, 2, 3
Standard Whipple procedure (with antrectomy) remains appropriate when there is proximal duodenal involvement or when the tumor is close to portal vein encasement 2
Total pancreatectomy should be limited to cases with diffuse pancreatic involvement without evidence of spread, as it offers no survival advantage and causes significant metabolic complications 2, 4
Left pancreatectomy (with splenectomy) is appropriate for localized tumors in the body and tail of the pancreas 2, 4
Extended lymphadenectomy has not shown survival advantages over standard lymphadenectomy and should not be routinely performed 4, 5

A feeding jejunostomy may be considered in patients with severe duodenopancreatic injuries requiring resection, though jejunostomy-related complications occur in up to 7% of patients 8, 9
Total parenteral nutrition may be required in a significant percentage of patients 8, 9

Five-year survival following resection for pancreatic cancer is approximately 10% 1, 2
Adjuvant therapy is required for all patients with resected pancreatic adenocarcinoma due to high recurrence rates 4, 5
Both gemcitabine and 5-FU based chemotherapy regimens have shown benefit in the adjuvant setting 3, 4
The role of adjuvant chemoradiation remains controversial, but may be considered for patients with R1 resections 3

Minimally invasive (laparoscopic and robotic) pancreaticoduodenectomy is being increasingly performed at specialized centers 4
Neoadjuvant therapy may be beneficial for patients with borderline resectable disease, potentially downstaging tumors and improving R0 resection rates 3, 4
Damage control surgery with staged procedures has been suggested for severe pancreatic-duodenal injuries requiring Whipple procedures in trauma settings 8, 9